Kaplan-Meier survival analysis demonstrated that high CD109 expression associated with poorer survival (P = 0.024) of patients with increasingly malignant, diffusively infiltrating astrocytomas (grades II–IV) (Figure 1C). Here, CD109 is linked to astrocytoma (excluding glioblastoma).